BioAge Labs, Inc. (NASDAQ:BIOA) Stock Has Consensus Target Price of $29.00 According to Analysts

BioAge Labs, Inc. (NASDAQ:BIOA – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $29.00.

BIOA has been the subject of several research analyst reports. Needham & Company LLC decreased their price objective on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Wall Street Zen cut BioAge Labs from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 10th. Roth Capital reissued a “buy” rating and issued a $25.00 target price on shares of BioAge Labs in a report on Wednesday, September 9th. Weiss Ratings raised BioAge Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Finally, Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a research report on Friday, July 31st.

View Our Latest Report on BIOA

Institutional Trading of BioAge Labs

Several hedge funds and other institutional investors have recently made changes to their positions in BIOA. Dimensional Fund Advisors LP acquired a new stake in BioAge Labs in the first quarter valued at $3,746,000. Renaissance Technologies LLC increased its position in BioAge Labs by 653.2% during the first quarter. Renaissance Technologies LLC now owns 138,588 shares of the company’s stock worth $2,424,000 after buying an additional 120,188 shares in the last quarter. Stempoint Capital LP acquired a new stake in BioAge Labs in the 1st quarter worth about $5,923,000. Bank of America Corp DE acquired a new stake in shares of BioAge Labs during the second quarter valued at about $6,320,000. Finally, Walleye Capital LLC acquired a new stake in BioAge Labs in the second quarter worth about $8,686,000.

BioAge Labs Stock Down 1.3%

BIOA stock opened at $4.71 on Friday. The business has a 50 day moving average price of $6.26 and a 200 day moving average price of $14.85. The stock has a market cap of $216.47 million, a price-to-earnings ratio of -1.85 and a beta of 1.19. BioAge Labs has a fifty-two week low of $4.45 and a fifty-two week high of $25.95.

BioAge Labs (NASDAQ:BIOA – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.05). BioAge Labs had a negative return on equity of 31.42% and a negative net margin of 1,253.60%. The company had revenue of $0.30 million for the quarter. As a group, sell-side analysts anticipate that BioAge Labs will post -2.59 EPS for the current year.

About BioAge Labs

(Get Free Report)

BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment. The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.

Recommended Stories

Analyst Recommendations for BioAge Labs (NASDAQ:BIOA)

Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.